Uveitis

A poll for retina specialists regarding their attendance at the 2022 Retina World Congress in Fort Lauderdale, Florida. This poll is now closed.

A poll for retina specialists regarding their attendance at the Association for Research in Vision and Ophthalmology 2022 Meeting in Denver, Colorado. This poll is now closed.

Bausch + Lomb and Clearside Biomedical Inc. are rolling out the new therapeutic, approved by the FDA for suprachoroidal use for the treatment of macular edema associated with uveitis.

A multifaceted evaluation that includes ultra-widefield imaging can reveal new information and influence treatment decisions.

Underlying autoimmune disease alters uveitis therapy.

XIPERE, the first therapy utilizing the suprachoroidal space, demonstrates rapid efficacy, durable benefit, and favorable safety profile.

Ankur Shah, MD, discusses key highlights of his presentation titled "YUTIQ CALM: a real-world registry study of the fluocinolone acetonide intravitreal implant 0.18 mg in chronic non-infectious posterior uveitis," during ASRS 2021.

Anterior uveitis therapy offers anti-inflammatory effect after dosing is stopped.

Quan Dong Nguyen, MD, MSc, FARVO, FASRS, speaks on the highlights of his presentation regarding new biological treatments of posterior uveitis.

Study examines immunomodulatory as a potential long-term treatment option.

Long-term sustained-release therapy pays off in management of chronic, vision-threatening disease.

While operating on a patient with chronic uveitis presents some challenges, there are a few pearls that may increase success.

Measures of inflammation can predict treatment outcomes for patients

Standardization of Uveitis Nomenclature (SUN) Working Group utilized machine learning to create new uveitis classification criteria, inciting hope for implementation in clinical and research settings.

PDUFA action date of October 30, 2021, is assigned for investigational therapy with a proposed indication of treatment of macular edema associated with uveitis.

Study results show the device offers an effective long-term option for patients.

Dexamethasone implant is key to treating non-infectious posterior segment uveitis

Studies highlight the need for specialists and training programs focusing on the disease.

Bradley Smith, MD, presents at AAO 2020 on how fingolimod 0.5 mg, a first-line treatment for multiple sclerosis, may reduce both the number of relapses and disease progression in patients with relapsing-remitting MS as well as the incidence of uveitis.

Glenn J. Jaffe, MD, presents a summary of the results of a confirmatory study on a previous Phase III trial that examined sustained drug delivery for the treatment of uveitis, as well as data on the 36-month results in the second, confirmatory phase 3 study of YUTIQ.

Chronic cases can be difficult for retina specialists; treatment is satisfying.

Inhibition plays role in autoimmune-based inflammation; has unique mechanism of action

One biologic response modifier has indication for uveitis; several in development to gain FDA approval

Quiescence, steroid-free quiescence achieved in VISUAL III trial

FA implant effective in lowering recurrence rates through available 6, 12 months of follow-up

Improvement in visual acuity, central retinal thickness, vitreous haze reported at 6 months

Intravitreal triamcinolone acetonide, dexamethasone implant superior for regional treatment of disorder